3 ms·
Editas and Broad only control the US market. It's extremely unlikely Broad will acquire such a strong position in Europe or Asia (in fact it's practically guara
by adventured 10y ago
Editas and Broad only control the US market. It's extremely unlikely Broad will acquire such a strong position in Europe or Asia (in fact it's practically guaranteed they will not).
If you had such a stellar therapy, and you couldn't get it past Editas, you'd go to Europe and partner with any number of a dozen other entities there that would be guaranteed to be interested (such as Novartis, which owns part of NTLA).